Jonathan Alspaugh - 23 Aug 2022 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (SYRE)

Role: Chief Financial Officer
Signature: /s/ James Kastenmayer, by power of attorney
Issuer symbol: SYRE
Transactions as of: 23 Aug 2022
Net transactions value: $0
Form type: 4
Filing time: 25 Aug 2022, 19:34:22 UTC
Previous filing: 15 Mar 2022
Next filing: 24 Feb 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AGLE	Employee Stock Option (right to buy)	Award	$0	+130,000		$0.000000	130,000	23 Aug 2022	Common Stock	130,000	$0.6800	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option vests and becomes exercisable in 48 equal monthly installments beginning on September 23, 2022 until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors, the stock option will vest as to 80% of the award by January 1, 2023, and 1/48 of the stock option will vest and become exercisable monthly thereafter until such time as the option is 100% vested.

Content

The stock option vests and becomes exercisable in 48 equal monthly installments beginning on September 23, 2022 until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors, the stock option will vest as to 80% of the award by January 1, 2023, and 1/48 of the stock option will vest and become exercisable monthly thereafter until such time as the option is 100% vested.